How to Manage Molecule Uncertainty: Nick Wigdahl on Portfolio Optimization and Pharma Lifecycle Strategy

About this episode

Nick Wigdahl discusses managing molecule uncertainty and its importance for mid-size life science companies.

“A 10% success rate means you have to be smart about every decision you make in the pipeline.” Nick Wigdahl , Director of PharmaGro, has spent his career navigating two worlds that rarely talk to each other: the operational complexity of big pharma and the portfolio discipline of family office investing. That combination, he argues, is exactly what mid-size life science companies need more of. Nick Wigdahl is Director of PharmaGro, a consultancy specializing in CMC, supply chain, market assessment, and portfolio management for mid-size pharmaceutical and CDMO companies. His background includes supply chain leadership roles at Roche and GSK, as well as investment and portfolio management experience with family offices in logistics and transportation. In the latest PharmaSource podcast episode, Nick explains why managing molecule uncertainty is one of the most underappreciated disciplines in pharma, and how companies that get it right make better investment decisions, optimize their portfolios, and build more resilient businesses. Read full article

People in this episode

Host: Life Science Networks

Guest: Nick Wigdahl

Topics covered

• molecule uncertainty
• portfolio optimization
• pharma lifecycle strategy
• mid-size life science companies
• investment decisions

Keywords

• molecule uncertainty
• portfolio management
• pharmaceutical industry
• investment strategy
• supply chain

Mentioned in this episode

Organizations: PharmaGro, Roche, GSK

More episodes of PharmaSource Podcast

• How Sanofi Navigates Regulatory CMC Across Global Markets: Insights from Manda Pasarkar · June 11, 2026 · 31 min
• The Politics Behind the Pipeline: How MFN Pricing and Tariffs Are Reshaping Pharma's Global Strategy · June 8, 2026 · 18 min
• How to Build a Resilient Global Vaccine Supply Chain: From Crisis to Capability · June 4, 2026 · 46 min
• How Lonza Is Outgrowing the CDMO Market with Bioconjugation, AI, and Regionalization · May 31, 2026 · 29 min
• The Strategic Partnership Gap: Why CDMOs Are Meeting Pharma's Expectations Less Than Half the Time with Simon-Kucher · May 27, 2026 · 26 min
• Creative Financing Strategies for Biotech's Bear Market, Beyond the VC Round · May 25, 2026 · 29 min